EDIT Stock Recent News
EDIT LATEST HEADLINES
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine just successfully navigated a key regulatory issue. Its reni-cel candidate now has a clearer path through its clinical trials.
Editas Medicine has recorded solid progress with its leading candidate. The biotech's financial position looks strong, given its clinical-stage status.
Editas Medicine's fourth-quarter results contained surprises. Financial results were better than expected.
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago.
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update.